Analysts have been eager to weigh in on the Healthcare sector with new ratings on NeoGenomics (NEO – Research Report) and Envista Holdings (NVST – Research Report).
NeoGenomics (NEO)
BTIG analyst Mark Massaro reiterated a Buy rating on NeoGenomics yesterday and set a price target of $21.00. The company’s shares closed last Wednesday at $13.96.
According to TipRanks.com, Massaro ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on NeoGenomics is a Strong Buy with an average price target of $21.00, a 50.0% upside from current levels. In a report issued on April 18, Leerink Partners also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Envista Holdings (NVST)
In a report released today, David Saxon from Needham maintained a Hold rating on Envista Holdings. The company’s shares closed last Wednesday at $19.75, close to its 52-week low of $18.96.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Envista Holdings with a $22.78 average price target, representing a 15.8% upside. In a report issued on April 26, Morgan Stanley also downgraded the stock to Hold with a $21.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NEO:
